Trellus Health plc (LSE:TRLS), which joined AIM in 2021, operates the Trellus Elevate® digital platform, combining data analytics, resilience-based training and expert support to help patients manage chronic conditions while reducing expensive hospital and emergency care usage. The company primarily focuses on chronic gastrointestinal diseases with significant mental health impacts and believes its methodology can be expanded into additional therapeutic areas over time.
Funding Constraints Force Strategic Review and Trading Suspension
The company said recent cost-cutting initiatives have extended its cash runway only until mid-June 2026. Trellus had previously reduced monthly cash burn to roughly $300,000 and relied on short-term financial support measures to preserve liquidity.
However, with long-term funding still unresolved and access to an existing convertible loan note facility limited by current market conditions, the company has engaged restructuring advisers to evaluate strategic alternatives. Options under consideration include the potential sale of its U.S. subsidiary. Trellus has also requested the suspension of trading in its AIM-listed shares due to limited working capital and ongoing financial uncertainty.
Weak Financial Position Continues to Weigh on Outlook
Trellus Health’s outlook remains constrained by weak financial performance, including substantial ongoing losses, negative free cash flow and declining equity levels, despite the benefit of operating without debt.
Technical indicators remain one of the few supportive factors, with the shares previously showing strong momentum above major moving averages. Nevertheless, valuation remains pressured by the company’s loss-making position and the absence of any indicated dividend yield.
More about Trellus Health PLC
Trellus Health plc is a healthcare technology business focused on value-based digital solutions for complex chronic conditions, particularly high-cost gastrointestinal diseases such as inflammatory bowel disease. Its Trellus Elevate® platform combines proprietary resilience-based methodologies, data analytics, technology tools and expert coaching to provide personalised whole-person condition management. The company also offers the Trellus TrialSet™ service for pharmaceutical industry partners.
Leave a Reply